Frexalimab

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameFrexalimab
Drug Alias NameINX-021SAR-441344
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCD40 ligand inhibitors
TargetsCD40 ligand
Therapy Area/IndicationsRejection of renal transplantationDiabetes Mellitus, Type 1Lupus Erythematosus, Systemic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesImmunext Inc
China Registration ClassN/A

Develop Information

Active CompaniesRoyalty Pharma PLCSanofiSanofi-Aventis Deutschland Gmbh +[5] 
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationDiabetes Mellitus, Type 1Lupus Erythematosus, Systemic +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A